Secondly, both the data and the compounds themselves are typically freely shareable in the open science sense (some may have published in paywalled journals and many have IP claims but these are implicitly waived). Thirdly, they can be seen as the future saviours of the drug discovery enterprise, commercial and academic. The basis of this bold claim is their conceived potential to illuminate 100s or even pushing towards 1000 new drug targets. This is the concept behind the druggable genome. If realised, this would become a boom for ADEV (see 'Far away from the lamppost', 2018, PMID 30532236). However, this stands in stark contrast to targets for currently approved drugs being well below 400 proteins (i.e. those under the lamppost). Indeed the current GtoPdb statistics indicates only 328 human primary targets of approved drugs. This implied slow rate of new successful targets thus seriously constrains ADEV (see 'Darkness in the Human Gene and Protein Function Space: Widely Modest or Absent Illumination by the Life Science Literature and the Trend for Fewer Protein Function Discoveries Since 2000 .